News & Updates
Filter by Specialty:
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
22 Jan 2025
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
A retrospective territory-wide cohort study by the Chinese University of Hong Kong (CUHK) reports an association between intermediate use of H1-antihistamines and longer overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs).
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
22 Jan 2025
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
21 Jan 2025
Increasing breast density elevates cancer risk
Women with large breasts are at greater risk of developing breast cancer, reveals a study, indicating the important role of mammographic density as first measured in determining subsequent risk.